<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: We explored the relationship between <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering agents and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality rates in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients, hypothesising a decreased risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality with <z:chebi fb="0" ids="6801">metformin</z:chebi> use and a dose-risk gradient for insulin therapy </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: This was a population-based cohort study using administrative data from Saskatchewan Health, Canada </plain></SENT>
<SENT sid="2" pm="."><plain>We identified new users of <z:chebi fb="0" ids="6801">metformin</z:chebi> or <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi> from 1 January 1991 to 31 December 1996, with follow-up until <z:hpo ids='HP_0011420'>death</z:hpo>, departure from the province or 31 December 1999 </plain></SENT>
<SENT sid="3" pm="."><plain>Cox regression analyses were used to estimate the HR of <z:hpo ids='HP_0011420'>death</z:hpo> from <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, accounting for time-varying exposure to <z:chebi fb="0" ids="6801">metformin</z:chebi>, <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi>, and exogenous insulin therapy </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: We identified 10,309 new users of <z:chebi fb="0" ids="6801">metformin</z:chebi> or <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>The average follow-up was 5.4 (1.9) years, during which 407 (4.0%) <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:hpo ids='HP_0011420'>deaths</z:hpo> occurred </plain></SENT>
<SENT sid="6" pm="."><plain>Adjusting for age, sex and <z:hpo ids='HP_0011010'>chronic</z:hpo> disease score, the adjusted HR for <z:chebi fb="0" ids="6801">metformin</z:chebi> use was 0.80 (95% CI 0.65-0.98) compared with <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> monotherapy users </plain></SENT>
<SENT sid="7" pm="."><plain>Adjusted HRs for subsequent insulin use were 2.22 (0.99-5.00), 3.33 (2.26-4.89) and 6.40 (4.69-8.73) for &lt;3, 3 to 11 and &gt; or = 12 insulin dispensations/year, respectively, compared with patients not on insulin </plain></SENT>
<SENT sid="8" pm="."><plain>We observed a similar risk gradient among the sub-cohort of new insulin users </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS/INTERPRETATION: Our results support previous reports of a decreased risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> outcomes associated with <z:chebi fb="0" ids="6801">metformin</z:chebi> use relative to <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> monotherapy </plain></SENT>
<SENT sid="10" pm="."><plain>We also provide new evidence of a gradient of cumulative insulin dispensations and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality rates </plain></SENT>
</text></document>